Abeona Therapeutics (ABEO) Q2 2026 earnings — TrendMatrix coverage
MISS · WIDER LOSS-42.9% vs estimateEPS -$0.35 vs -$0.24 est
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
Key numbers
- Reported EPS
- -$0.35
- Estimate
- -$0.24
- Surprise
- -42.9%
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Report record · Q2 2026
How the report landed
Abeona Therapeutics (ABEO) reported a wider loss than forecast — diluted EPS of -$0.35 against the -$0.24 estimate (a 42.9% shortfall).
Around the report
Coverage in the report window
- Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21 — benzinga, 2026-08-14
- Abeona Therapeutics Q2 2026 Earnings Call Transcript — benzinga, 2026-08-13
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session — benzinga, 2026-08-13